Image may be NSFW.
Clik here to view.
Originally posted on Orphan Druganaut Blog:
.
.
The chart below identifies orphan drug designated products receiving FDA approval in April 2014 (as of 05/03/14) in ascending “Approval Date” order.
FDA April 2014 Orphan Drugs Receiving Approval
| # | Generic Name/Approval Date | Sponsor Company | Indication |
| 1 | ethiodized oil injection (Lipiodol)/ 04.04 | Guerbet LLC | Imaging tumors in adults with known hepatocellular carcinoma (HCC) |
| 2 | Ramucirumab (Cyramza)/ 04.21 | Eli Lilly and Company | Gastric Cancer or gastro-esophageal junction adenocarcinoma |
| 3 | Siltuximab (Sylvant)/ 04.23 | Janssen Biotech | Multicentric Castleman’s Disease (MCD) |
| 4 | Mercaptopurine/ 04.28 | Nova Laboratories Limited (UK) | Acute Lymphoblastic Leukemia (ALL) |
| 5 | Ceritinib (Zykadia)/ 04.29 | Novartis Pharmaceuticals Corp | ALK+ metastatic non-small cell lung cancer (NSCLC) who have progressed onor are intolerant
to crizotinib |
.
Please Note: FDA Official Logo from FDA website.
Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.
Filed under: Uncategorized Image may be NSFW.
Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
